HRC

ANALYST NOTE: HRC (Hill-Rom Holdings, Inc.) Date: 2026-06-13 Current Price: $155.96

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 0.2% (Sub-threshold)

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None Named

At this date, HRC is not anchored to a named macro or secular thesis (e.g., "aging demographics" or "global health infrastructure build-out" are not explicitly cited as the primary driver in the provided evidence). The investment case is strictly tactical and setup-led.

The conviction must be derived entirely from the quality of the technical structure (which is currently absent) and the underlying business fundamentals. There is no "thesis membership" to weight the conviction. The analyst must judge the name solely on whether the business fundamentals support a future structural breakout, but as of 2026-06-13, the setup itself provides no directional bias.

3. Business Analysis

Company Profile: Hill-Rom Holdings, Inc. operates as a global enterprise in the medical technology sector, structured into three primary operational areas: Patient Support Systems, Front Line Care, and Surgical Solutions (Evidence E8).

Operational Segments & Evidence:

• Patient Support Systems: This division provides essential equipment including medical-surgical, ICU, and bariatric patient beds, patient lifts, non-invasive therapeutic surfaces, and associated IT/software. The segment also generates recurring revenue through service contracts for its capital equipment (Evidence E9, E10).
• Front Line Care: This area encompasses general patient examination and diagnostic tools, continuous patient monitoring systems, diagnostic cardiology products, and vision screening devices. It also supplies a suite of respiratory health products, including the Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000, designed to facilitate the mobilization of retained blockages (Evidence E11, E12).
• Surgical Solutions: This segment delivers critical operating room infrastructure, including surgical tables, specialized lighting, and ceiling-mounted pendants. It also manufactures precision positioning devices for procedures such as shoulder, hip, spinal, and lithotomy surgeries, along with universal positioning accessories (Evidence E13, E14).

Market Reach: The company distributes products to a broad spectrum of healthcare providers, selling and renting directly to individual patients for home use, and supplying primary care facilities via distribution partners (Evidence E15, E16).

Historical Performance Context (Source Date: 2021-07-30): While the current date is 2026, the only available earnings evidence is from the 2021 fiscal year. As of that period, management reported:

• Earnings Beat: Adjusted earnings of $1.38 exceeded the guidance range of $1.32 to $1.36 (Evidence E1).
• Guidance Raise: Management raised financial guidance for fiscal 2021 citing strong performance and positive recovery dynamics (Evidence E2).
• Growth Drivers: Excluding a one-time $130 million COVID benefit from the prior year, revenue growth was 10% (Evidence E3).
• Connected Care: 30% of revenue was derived from connected care devices, growing at 20% (Evidence E5).
• Large Deal: A significant multi-quarter deal was underway with orders being received and shipped, with revenue recognition expected in the fourth quarter (Evidence E6).
• International Traction: Double-digit growth in China was recorded for eight of the last nine quarters (Evidence E7).

*Note: No financial data, guidance, or operational updates are available in the evidence base for the period between 2021 and the current date of 2026-06-13.*

4. Archetype and Conviction

Archetype: Growth Leader Fit Rationale: The company fits the Growth Leader archetype based on the historical evidence of double-digit revenue growth, a high mix of connected care devices (20% growth), and successful execution of large-scale deals. The business model relies on a mix of capital equipment sales and recurring service contracts, which supports a compounder profile.

Conviction Stack:

• Thesis Strength: Low. No named secular thesis is active at this date.
• Evidence Quality: Mixed. The evidence base is heavily skewed toward 2021 performance. There is a significant gap in data regarding the company's performance, guidance, or strategic shifts between 2021 and 2026.
• Structural Quality: Null. The setup is not formed.
• Rerating Potential: Unknown. Without current financials or a technical breakout, rerating potential cannot be assessed.

ATR Context: The current ATR of 0.2% is sub-threshold (<2.5%). In the StoryStocks canon, this indicates weak volatility and a lack of institutional participation or momentum. Historically, setups with sub-threshold ATR often lack the "fuel" for a sustained move until volatility expands. This is a negative structural signal for immediate entry, reinforcing the "context-only" status.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case:

• Fundamental: A significant deviation from the historical growth trajectory (e.g., a multi-year decline in connected care revenue or failure to execute large deals) would weaken the "Growth Leader" archetype.

What Would Strengthen the Case:

• Fundamental: New earnings data (post-2021) confirming sustained double-digit growth, successful integration of the "large deal" mentioned in 2021, or expansion of the China market beyond the historical 8-of-9 quarters trend.

Gaps in Evidence Base:

• Critical Missing Data: There is no evidence for the period from 2022 through 2026. The analysis relies entirely on 2021 earnings transcripts and a 2026 company profile cache.
• Missing Financials: No revenue, earnings, or guidance figures exist for the current fiscal year (2026).
• Missing Technicals: No pivot levels, volume profiles, or recent price action history are provided to construct the coil.
• Missing Management Expectations: No forward-looking statements from management for 2026 are available to frame expectations.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key risks: 1) Fundamental performance may have diverged significantly from 2021 trends; 2) Technical structure may be invalid if price is below a hidden support level; 3) Lack of current guidance creates blind spot on valuation. Sizing hint: Zero position size until structure forms and current financials are available. Expected horizon: Indefinite until structural and fundamental data gaps are filled. Failure mode to watch: The price action remains range-bound with sub-threshold volatility for an extended period, indicating a lack of institutional interest or a fundamental stagnation.